Background: Some clinical studies have reported the alteration of serum brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) level before and after the antidepressant treatments in patients with major depressive disorder (MDD). We evaluated serum BDNF and GDNF levels before and after the 12-week antidepressant treatments in MDD outpatients. Methods: Serum BDNF and GDNF levels were measured in 28 MDD outpatients. The severity of depression was measured with the Hamilton Depression Rating Scale (HAMD). Results: Serum BDNF and GDNF levels were significantly decreased after the 12-week antidepressant treatments with comparison of those before the treatments (p<0.05). The baseline serum BDNF and GDNF levels in the remission group were higher than in non-remission group, but that were not statistically significant. Conclusions: Our study revealed a reduction of serum BDNF and GDNF levels after the antidepressant treatments in MDD outpatients. Key Words: brain-derived neurotrophic factor · glial cell linederived neurotrophic factor · major depression · remission Psychiatry, Taipei Veterans General Hospital, Taiwan No. 201, Shi-Pai Road, Section 2, Taipei 112, Taiwan, Tel: +886-2-28757027-298, Fax: +886-2-28757592 E-mail: ctli2@vghtpe.gov.tw Abstract Background: The relationship between severe inflammation and clinical depression in the context of major medical illnesses has been addressed, but the relationship between mild infections/ inflammation and clinical depression is unclear. We aimed to examine whether a history of repeated low-grade infections/ inflammation (RLGI) in medically healthy subjects (MHS) could increase the vulnerability to major depressive disorder (MDD) and whether RLGI could be associated with higher resistance to antidepressants in those developing MDD. Methods: A nationwide population-based cohort study (1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011) was conducted for MHS with and without a history of RLGI. The rates of MDD during an up to 8-year follow-up period were compared between the two groups in two independent cohorts. The stratified responses to antidepressants, including easy-totreat and difficult-to-treat responses, were also compared in the MDD patients. Results: During the follow-up, the two cohorts consistently revealed that the RLGI(+) group had a significantly higher chance of developing MDD over time than the RLGI(-) group. Cox-PH regression models showed that the hazard ratio associated with a history of RLGI was 1.369 to 1.911 (p<0.001), after adjusting for confounding factors. MDD patients in the RLGI(+) group consistently presented higher ratios of difficult-to-treat responses to sequential antidepressant trials in adequate doses than those in the RLGI(-) group (cohort-2002: 11.5% vs. 7.6%; cohort-2004: 11.8% vs. 4.3%, both p<0.05). Conclusion: This is the first large-scale study to report a reliable temporal association between a history of RLGI and subsequent diagnosis of MDD and poor responses to antidepressants. Our dada support the view that chronic inflammation plays a role in the pathophysiology of MDD and antidepressant-resistant depression.
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Title: Digit span-forward as a predictor of fluoxetine outcome for patients with major depressive disorder Ching-Hua Lin, MD, PhD*; Fu-Chiang Wang, MD Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan Abstract Objective: The objective of this paper was to determine whether baseline subtests and intelligence quotient (IQ) using Wechsler Adult Intelligence Scale (WAIS-III) were associated with treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment. Methods: A total of 131 acutely ill MDD inpatients were enrolled to receive 20mg of fluoxetine daily for 6 weeks. WAIS-III with 8 subtests (picture completion, digit symbol, similarities, block design, arithmetic, digit span-forward, digit span-backward, and information) were rated by licensed clinical psychologist at baseline. Symptom severity and functional impairment were assessed at baseline, and again at weeks 1, 2, 3, 4, and 6 using the 17-item Hamilton Depression Rating Scale (HAMD-17) and Modified Work and Social Adjustment Scale (MWSAS) respectively. The generalized estimating equations method was used to analyze the influence of IQ scores and 8 subtest raw scores on the HAMD-17 and MWSAS over time after adjusting for sex, age, age at onset of illness, numbers of previous episode, and baseline severity (baseline HAMD-17 or MWSAS), respectively. Results: Of the 131 participants, 104 (79.4%) who completed baseline measurements using WAIS-III and had at least one postbaseline assessment were included in the analysis. Subjects had low verbal IQ (VIQ) scores (88.8 ± 13.7), performance IQ (PIQ) scores (83.7 ± 14.7), and full scaled IQ (FSIQ) scores (86.4 ± 12.9) than general population norms. PIQ scores were lower than VIQ scores. Patients experiencing less digit span-forward scores were more likely to have poor treatment outcomes regardless of symptom severity measured by HAMD-17 or functioning measured by MWSAS. Conclusions: Discrepancy existing between VIQ and PIQ may be attributed to psychomotor retardation, a general slowing of mental processes recognized as a depressive symptom. MDD patients with lower scores of digital forwards were clinically useful in predicting poor outcomes after acute fluoxetine treatment.
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Cognitive impairment of remitted depression in medication with anticholinergic activity 
Showa University School of Medicine, Japan
Abstract Objective: It is widely reported that cognitive impairment emerges in remitted depression. However, it has been suggested that the cognitive impairment may either persist due to the disorder despite effective antidepressant (ADT) treatment or emerge as a side effect of the ADT treatment itself. The aim of our study was to clarify whether anticholinergic effect influenced to the cognitive impairment in remitted depression. Methods: A total of 49 inpatients with MDD (DSM-IV) after remission (HAM-D ≤ 7) were recruited. A total of 67 healthy participants were recruited as control group. For all subjects, two cognitive tests were conducted; logical memory (LM) of the Wechsler Memory Scale Revised (WMS-R), Stroop Color and Word Test (Stroop). In addition, we collected blood samples at study entry, and measured serum anticholinergic activity (SAA) as anticholinergic effect using a radio-receptor assay technique which was developed by Tune and Coyle. We divided all MDD patients into two groups: those with positive SAA [SAA (+), n=28] and those with negative SAA [SAA (-), n=21]. Any SAA level greater than the detection of limit of a quantitative level (≥1.95 pmol / ml) is defined as SAA (+). The present study was approved by the Medical Ethics Committee of Juntendo University. All participants provided written informed consent. Results: The scores of LM of WMS-R and Stroop were significantly lower in SAA (+) than those in healthy controls (p < 0.001, Mann-Whitney U). In SAA (-) group, Scores of LM of WMS-R were significantly lower than those in healthy controls (p = 0.047, Mann-Whitney U). For Multiple regression analysis, SAA levels had a significant effect on LM of WMS-R (p = 0.005). Conclusions: Anticholinergic effect with ADT may influence to a part of cognitive impairment in remitted depression. Especially, memory impairment may be affected with the anticholinergic level.
